Limited proteolysis of tumor cells increases their plasmin-binding ability

Mild proteolytic treatment of SW 1116 tumor cells with trypsin or plasmin increases their plasmin-binding ability considerably by increasing the number of binding sites without altering their affinity. This mechanism may be operative for increasing the concentration of active plasmin at the surface...

Full description

Saved in:
Bibliographic Details
Published inFEBS letters Vol. 245; no. 1; pp. 21 - 24
Main Authors Camacho, Mercedes, Fondaneche, Marie-Claude, Burtin, Pierre
Format Journal Article
LanguageEnglish
Published England Elsevier B.V 13.03.1989
Subjects
Aprotinin - pharmacology
Carboxypeptidase B
Carboxypeptidases - pharmacology
Colonic Neoplasms - metabolism
Electrophoresis, Polyacrylamide Gel
Fibrinogen - physiology
Fibrinolysin - metabolism
Fibrinolysin - pharmacology
Humans
Lysine
Lysine-binding site
Peptide Hydrolases - pharmacology
Plasmin
Trypsin - pharmacology
Tumor cell
tumor cells
Tumor Cells, Cultured
Lysine-binding site
Lysine
Plasmin
Tumor cell
Online AccessGet full text

Cover

More Information
Summary:Mild proteolytic treatment of SW 1116 tumor cells with trypsin or plasmin increases their plasmin-binding ability considerably by increasing the number of binding sites without altering their affinity. This mechanism may be operative for increasing the concentration of active plasmin at the surface of tumor cells. C-terminal lysine residues are involved in plasmin binding to cells, since treatment of cells with carboxypeptidase B decreases this binding by 50%.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0014-5793
1873-3468
DOI:10.1016/0014-5793(89)80183-8